Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Anti-interleukin 5 Receptor Therapy (Benralizumab) in Patients With Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS)

NCT06734884 is registered in ClinicalTrials.gov with University Hospital, Lille as lead sponsor.

NCT NCT06734884
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06734884 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Anti-interleukin 5 Receptor Therapy (Benralizumab) in Patients With Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS)
Lead sponsor
University Hospital, Lille
Phase
Phase 2
Overall status
Not yet recruiting
Start date
January 6, 2027
Completion date
September 1, 2029
Enrollment
96 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

dress syndrome